Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - prednisolone - oral tablet - 1mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

strides pharma uk ltd - prednisolone - oral tablet - 1mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - prednisolone - oral tablet - 1mg

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

viatris limited - efavirenz 600mg;  ; emtricitabine 200mg;  ; tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil - film coated tablet - active: efavirenz 600mg   emtricitabine 200mg   tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil excipient: colloidal silicon dioxide croscarmellose sodium hyprolose low-substituted hydroxypropylcellulose, lh 11 iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 85f540043 sodium metabisulfite - indicated for the treatment of hiv infected adults over the age of 18 years, alone or in combination with other antiretroviral agents.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - emtricitabine, quantity: 200 mg; efavirenz, quantity: 600 mg; tenofovir disoproxil maleate, quantity: 300 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium metabisulfite; hyprolose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; ferric oxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - tenofovir disoproxil/ emtricitabine/ efavirenz mylan 300/200/600 is indicated for the treatment of hiv infected adults over the age of 18 years.,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts in controlled studies of viread, emtriva and stocrin in treatment-na?ve and treatment experienced adults.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phenylephrine hydrochloride, quantity: 5 mg/ml - spray, solution - excipient ingredients: purified water; sodium chloride; sodium hydroxide; thiomersal; hydrochloric acid; sodium citrate dihydrate - relieves nasal congestion in colds, flu, allergy, hayfever and sinusitis.

САЩ - английски - NLM (National Library of Medicine)

mylan specialty l.p. - pretomanid (unii: 2xoi31yc4n) (pretomanid - unii:2xoi31yc4n) - limited population: pretomanid tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (tb) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug or adults with pulmonary tb resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. approval of this indication is based on limited clinical safety and efficacy data. this drug is indicated for use in a limited and specific population of patients. limitations of use: pretomanid tablets used in the combination regimen with bedaquiline and linezolid are contraindicated in patients for whom bedaquiline and/or linezolid are contraindicated. refer to the bedaquiline and linezolid prescribing information. there are no studies or available data on pretomanid use in pregnant women to inform any drug-associated risks. there are risks associated with active tuberculosis during pregnancy (see cl

Израел - английски - Ministry of Health

j-c health care ltd - cobicistate; darunavir as ethanolate - film coated tablets - cobicistate 150 mg; darunavir as ethanolate 800 mg - darunavir - rezolsta is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv 1) infection in treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions (v11i, v32i, l33f, i47v, i50v, i54l, i54m, t74p, l76v, i84v, l89v).שינוי משטר מינון 2/4/2019pregnancy and postpartumtreatment with rezolsta during pregnancy results in low darunavir exposure (see sections 4.4 and 5.2). therefore, therapy with rezolsta should not be initiated during pregnancy, and women who become pregnant during therapy with rezolsta should be switched to an alternative regimen, see section 4.4 and 4.6. darunavir/ritonavir may be considered as an alternative.

Малта - английски - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - rifampicin - powder and solvent for solution for infusion - rifampicin 600 mg - antimycobacterials

Канада - английски - Health Canada

salix pharmaceuticals inc - rifaximin - tablet - 550mg - rifaximin 550mg - rifamycins